Italian cancer figures - Report 2014 Prevalence and cure of cancer in Italy;I tumori in Italia - Rapporto 2014 Prevalenza e guarigione da tumore in Italia

Epidemiologia e Prevenzione

Volumn 38, Issue 6, 2014, Pages 1-144

  Dal Maso, Luigino ^a   Guzzinati, Stefano ^b   De Angelis, Roberta ^c   Virdone, Saverio ^a   Buzzoni, Carlotta ^d   Baili, Paolo ^e   Busco, Susanna ^f   Capocaccia, Riccardo ^c,e   Cascone, Giuseppe ^g   Di Felice, Enza ^h   Ferretti, Stefano ⁱ   Foschi, Roberto ^e   Francisci, Silvia ^c   Gatta, Gemma ^e   Gigli, Anna ^j   Mallone, Sandra ^c   Rossi, Silvia ^c   Trama, Annalisa ^e   Vicentini, Massimo ^h   Crocetti, Emanuele ^d  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Registro Tumori del Veneto   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d ISTITUTO TOSCANO TUMORI   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f Registro Tumori di Popolazione della Provincia di Latina   (Italy)

^g Azienda sanitaria provinciale   (Italy)

^h PATHOLOGY UNIT   (Italy)

ⁱ Azienda USL Ferrara   (Italy)

^j Istituto Di Ricerche Sulla Popolazione E Le Politiche Sociali Rome   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGED; FEMALE; HUMAN; ITALY; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; PREVALENCE; REGISTER; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; REGISTRIES; SURVIVAL RATE;

EID: 84938075454     PISSN: 11209763     EISSN: 23851937     Source Type: Journal    
DOI: None     Document Type: Article

References (173)

1. AIRTUM 2014. ITACAN: Tumori in Italia, Versione 2.0. Associazione Italiana dei Registri TUMori. Available at: http://itacan.ispo.toscana.it/italian/itacan.htm
2. AIRTUM Working Group. Italian cancer figures, report 2012: Cancer in children and adolescents. Epidemiol Prev 2013;37(1) Suppl 1:1-296. Available at: http://www.registri-tumori.it
3. De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15(1):23-34.
4. AIOM, CCM, AIRTUM Working Group . I numeri del cancro in Italia 2013. Brescia, Intermedia Editore, 2013. Available at: http://www.registri-tumori.it/cms/it/node/2888
5. Osservatorio sulla condizione assistenziale dei malati oncologici (ed). Sesto rapporto sulla condizione assistenziale dei malati oncologici. Roma, Editore Il Sole 24 Ore Sanità, 2014. Available at: http://www.favo.it/sesto-rapporto/sesto-rapporto-2014.html
6. AIRTUM Working Group. Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients. Epidemiol Prev 2010; 34(5-6) Suppl 2:1-188. Available at: http://www.registri-tumori.it/cms/?q=Rapp2010.
7. McCabe MS, Bhatia S, Oeffinger KC et al. American society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 2013;31(5):631-40.
8. Baade PD, Youlden DR, Chambers SK. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust 2011;194(2):73-7.
9. Erratum in: Med J Aust 2011;194(7):376.
10. Dal Maso L, Guzzinati S, Buzzoni C et al; AIRTUM Working Group. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol 2014;25(11):2251-60.
11. Francisci S, Capocaccia R, Grande E et al; EUROCARE Working Group. The cure of cancer: a European perspective. Eur J Cancer 2009;45(6):1067-79.
12. Janssen-Heijnen MLG, Gondos A, Bray F et al. Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. J Clin Oncol 2010;28(15):2520-8.
13. Capocaccia R, De Angelis R. Estimating the completeness of prevalence based on cancer registry data. Stat Med 1997;16(4):425-40.
14. AIRTUM Working Group. Italian cancer figures, report 2013: Multiple tumours. Epidemiol Prev 2013; 37(4-5) Suppl 1. Available at: http://www.registri-tumori.it/cms/it/Rapp2013.
15. De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 1999;18(4):441-54.
16. Guzzinati S, Buzzoni C, De Angelis R et al; AIRTUM Working Group. Cancer prevalence in Italy: an analysis of geographic variability. Cancer Causes Control 2012;23(9):1497-510.
17. AIRTUM Working Group. Italian cancer figures, report 2011. Survival of cancer patients in Italy. Epidemiol Prev 2011;35(5-6) Suppl 3:1-200. Available at: http://www.registri-tumori.it/cms/Rapp2011.
18. Rossi S, Capocaccia R, De Angelis R, Gatta G (eds). Cancer burden in Italian regions. Tumori 2013;99(3):416-24.
19. Micheli A (ed). Cancer prevalence in Italy: the ITAPREVAL study. ITAPREVAL Working Group. Tumori 1999;85(5):307-420
20. Crocetti E, De Angelis R, Buzzoni C et al; AIRTUM Working Group. Cancer prevalence in United States, Nordic Countries, Italy, Australia, and France: an analysis of geographic variability. Br J Cancer 2013;109(1):219-28.
21. Colonna M, Danzon A, Delafosse P et al. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer 2008;44(1):115-22.
22. Engholm G, Ferlay J, Christensen N et al. NORDCAN - a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 2010;49(5):725-36.
23. SEER (2012) SEER*Stat Database: Incidence-SEER 9 Registries Research Data, Sub (1973-2006). Available at: www.seer.cancer.gov.
24. AIHW (Australian Institute of Health and Welfare). Australian Cancer Incidence and Mortality Books. Canberra, AIHW ACIM, 2010.
25. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97(1):72-81.
26. Smastuen M, Aagnes B, Johannsen TB et al. Long-term cancer survival: patterns and trends in Norway 1965-2007. Oslo, Cancer Registry of Norway, 2008.
27. Janssen-Heijnen MLG, van Steenbergen LN, Voogd AC et al. Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands. Ann Oncol 2014;25(1):64-8.
28. Woods LM, Rachet B, Lambert PC, Coleman MP. 'Cure' from breast cancer among two populations of women followed for 23 years after diagnosis. Ann Oncol 2009;20(8):1331-6.
29. Gatta G, Capocaccia R, Berrino F et al; EUROPREVAL Working Group. Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Ann Oncol 2004;15(7):1136-42.
30. Lambert PC, Dickman PW, Osterlund P, Andersson T, Sankila R, Glimelius B. Temporal trends in the proportion cured for cancer of the colon and rectum: a population-based study using data from the Finnish Cancer Registry. Int J Cancer 2007;121(9):2052-9.
31. Andrae B, Andersson TML, Lambert PC et al. Screening and cervical cancer cure: population based cohort study. BMJ 2012;344:e900.
32. Sinn M, Striefler JK, Sinn BV et al. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. J Surg Oncol 2013;108(6):398-402.
33. Simonetti A, Gigli A, Capocaccia R, Mariotto A. Estimating complete prevalence of cancers diagnosed in childhood. Stat Med 2008;2787):990-1007.
34. Baili P, Vicentini M, Tumino R et al. A method for differentiating cancer prevalence according to health status, exemplified using a population-based sample of Italian colorectal cancer cases. Acta Oncol 2013;52(2):294-302.
35. Francisci S, Guzzinati S, Mezzetti M et al. Cost profiles of colorectal cancer patients in Italy based on individual patterns of care. BMC Cancer 2013;13:329.
36. Gigli A, Warren, Yabroff et al. Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States. J Natl Cancer Inst Monogr 2013;2013(46):88-98.
37. Micheli A, Ciampichini R, Oberaigner W et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer 2009;45(6):1017-27.
38. Othus M, Barlogie B, Leblanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res 2012;18(14):3731-6.
39. Yu XQ, De Angelis R, Andersson TM, Lambert PC, O'Connell DL, Dickman PW. Estimating the proportion cured of cancer: some practical advice for users. Cancer Epidemiol 2013;37(6):836-42.
40. Trama A, Mallone S, Ferretti S, Meduri F, Capocaccia R, Gatta G; RITA Working Group. The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) Project. Tumori 2012;98(5):550-8.
41. Mallone S, De Angelis R, van der Zwan JM et al. Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. Cancer Epidemiol 2013;37(6):850-6.
42. www.registri-tumori.it
43. AIRTUM Working Group. Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients. Epidemiol Prev 2010;34(5-6) Suppl 2:1-188.
44. AIRTUM Working Group. Italian cancer figures, report 2011: Survival of cancer patients in Italy. Epidemiol Prev 2011;35(5-6) Suppl3:1-200. Available at: http://www.registri-tumori.it/cms/Rapp2011
45. AIRTUM Working Group; CCM; AIEOP Working Group. Italian cancer figures, report 2012: Cancer in children and adolescents. Epidemiol Prev 2013;37(1) Suppl 1:1-225.
46. AIRTUM Working Group. Italian cancer figures, report 2013: Multiple tumours. Epidemiol Prev 2013;37(4-5) Suppl 1:1-152.
47. Protocollo operativo per la gestione della Banca Dati AIRTUM - 2.0 (Database AIRTUM Protocol). Available at: http://www.registri-tumori.it/cms/files/2010.pdf
48. Curado MP, Edwards B, Shin HR et al (eds). Cancer Incidence in Five Continents. Vol. IX. IARC Scientific Publication No. 160. Lyon, IARC, 2007. Available at: http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/CI5vol9-A.pdf
49. Forman D, Bray F, Brewster DH et al (eds). Cancer Incidence in Five Continents, Vol. X. Lyon, IARC, 2013. Available at: http://ci5.iarc.fr
50. HAEMACARE Working Group. Manual for coding and reporting haematological malignancies. Tumori 2010;96(4):i-A32. Available at: http://www.tumorionline.it/pdf/HAEMACARE.pdf
51. Turner JJ, Morton LM, Linet MS et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010;116(20):e90-8.
52. Capocaccia R, De Angelis R. Estimating the completeness of prevalence based on cancer registry data. Stat Med 1997;16(4):425-40.
53. Merrill RM, Capocaccia R, Feuer EJ, Mariotto A. Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) Program. Int J Epidemiol 2000; 29(2):197-207.
54. ISTAT 2014. Available at: http://www.demo.istat.it/
55. Complete Prevalence (ComPrev) Software, Version 2.0 released April 2011. National Cancer Institute. Available at: http://surveillance.cancer.gov/comprev/
56. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19(6):716-23.
57. Yu XQ, De Angelis R, Andersson TM, Lambert PC, O'Connell DL, Dickman PW. Estimating the proportion cured of cancer: some practical advice for users. Cancer Epidemiol 2013;37(6):836-42.
58. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No.10, End Results Evaluation Section. National Cancer Institute, Bethesda MD,1950.
59. De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 1999;18(4):441-54.
60. Dal Maso L, Guzzinati S, Buzzoni C et al. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol 2014, 25(11): 2251-60.
61. Francisci S, Capocaccia R, Grande E et al. The cure of cancer: a European perspective. Eur J Cancer 2009;45(6):1067-79.
62. Lambert PC, Dickman PW, Weston CL, Thompson JR. Estimating the cure fraction in population-based cancer studies by using finite mixture models. Applied Statistics 2010;59(1):35-55.
63. Andersson TM, Dickman PW, Eloranta S, Lambert PC. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol 2011;11:96.
64. Othus M, Barlogie B, Leblanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res 2012; 18(14):3731-6.
65. Cvancarova M, Aagnes B, Fosså SD, Lambert PC, Møller B, Bray F. Proportion cured models applied to 23 cancer sites in Norway. Int J Cancer 2013;132(7):1700-10.
66. Smastuen M, Aagnes B, Johannsen TB, Møller B, Bray F. Long-term cancer survival: patterns and trends in Norway 1965-2007. Oslo, Cancer Registry of Norway, 2008. Available at: www.kreftregisteret.no/Global/Publikasjoner%20og%20rapporter/CIN2007_del2.pdf
67. Janssen-Heijnen ML, van Steenbergen LN, Voogd AC et al. Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands. Ann Oncol 2014;25(1):64-8.
68. Baade PD, Youlden DR, Chambers SK. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust 2011;194(2):73-7.
69. Lambert PC, Dickman PW, Osterlund P, Andersson T, Sankila R, Glimelius B. Temporal trends in the proportion cured for cancer of the colon and rectum: a population-based study using data from the Finnish Cancer Registry. Int J Cancer 2007;121(9):2052-9.
70. Andersson TM, Lambert PC, Derolf AR et al. Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study. Br J Haematol 2010;148(6):918-24.
71. Woods LM, Rachet B, Lambert PC, Coleman MP. 'Cure' from breast cancer among two populations of women followed for 23 years after diagnosis. Ann Oncol 2009;20(8):1331-6.
72. Janssen-Heijnen MLG, Gondos A, Bray F et al. Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. J Clin Oncol 2010;28(15):2520-8.
73. Ellison LF, Bryant H, Lockwood G, Shack L. Conditional survival analyses across cancer sites. Health Rep 2011;22(2):21-5.
74. Andrae B, Andersson TM, Lambert PC et al. Screening and cervical cancer cure: population based cohort study. BMJ 2012;344:e900.
75. Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med 2002;21(22):3511-26.
76. Mariotto AB, Yabroff KR, Feuer EJ, De Angelis R, Brown M. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control 2006;17(10): 1215-26.
77. Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH. Cancer survivors: a booming population. Cancer Epidemiol Biomarkers Prev 2011;20(10):1996-2005.
78. Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer 2009; 45(5):756-64.
79. de Moor JS, Mariotto AB, Parry C et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013; 22(4):561-70.
80. ISTAT 2014. Available at: http://demo.istat.it/uniprev2011/index.html
81. Micheli A; ITAPREVAL Working Group (eds). Cancer prevalence in Italy: the ITAPREVAL study. Tumori 1999;85(5):307-420.
82. AIRTUM Working Group. Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients. Epidemiol Prev 2010;34(5-6) Suppl 2:1-188. Available at: http://www.registri-tumori.it/cms/?q=Rapp2010
83. AIRTUM 2014. ITACAN: Tumori in Italia, Versione 2.0. Available at: http://itacan.ispo.toscana.it/italian/itacan.htm
84. Rossi S, Capocaccia R, De Angelis R, Gatta G (eds). Cancer burden in Italian regions. Tumori 2013;99(3):416-24.
85. Baili P, Hoekstra-Weebers J, Van Hoof E et al. Cancer rehabilitation indicators for Europe. Eur J Cancer 2013;49(6):1356-64.
86. Crocetti E, De Angelis R, Buzzoni C et al; AIRTUM Working group. Cancer prevalence in United States, Nordic Countries, Italy, Australia, and France: an analysis of geographic variability. Br J Cancer 2013;109(1):219-28.
87. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 2012;107(7):1195-202.
88. Gatta G, Rossi S, Capocaccia R. Cancer burden estimates and forecasts: uses and cautions. Tumori 2013;99(3):439-43.
89. Yabroff KR, Francisci S, Mariotto A, Mezzetti M, Gigli A, Lipscomb J. Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities. J Natl Cancer Inst Monogr 2013;2013(46):1-6.
90. Brown MC, Levitt GA, Frey E et al; on behalf of the PanCareSurFup Consortium. The views of European clinicians on guidelines for long-term follow-up of childhood cancer survivors. Pediatr Blood Cancer 2014. [Epub ahead of print]
91. Skinner R, Wallace WH, Levitt G. Long-term follow-up of children treated for cancer: why is it necessary, by whom, where and how? Arch Dis Child 2007;92(3):257-60.
92. Haupt R, Jankovic M, Hjorth L, Skinner R. Late effects in childhood cancer survivors and survivorship issues. Epidemiol Prev 2013;37(1) Suppl 1:266-73.
93. Simonetti A, Gigli A, Capocaccia R, Mariotto A. Estimating complete prevalence of cancers diagnosed in childhood. Stat Med 2008; 27(7):990-1007.
94. Capocaccia R, De Angelis R. Estimating the completeness of prevalence based on cancer registry data. Stat Med 1997;16(4):425-40.
95. Corazziari I, Mariotto A, Capocaccia R. Correcting the completeness bias of observed prevalence. Tumori 1999;85(5):370-81.
96. Mallone S, De Angelis R, van der Zwan JM et al; RARECARE Working Group. Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. Cancer Epidemiol 2013;37(6):850-6.
97. ISTAT lifetables. Available at: http://demo.istat.it/unitav2012/
98. Mariotto AB, Rowland JH, Yabroff KR et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 2009;18(4):1033-40.
99. American Cancer Society. Cancer Facts and Figures 2014. Atlanta 2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf
100. AIRTUM Working Group, CCM; AIEOP Working Group. Italian cancer figures, report 2012: Cancer in children and adolescents. Epidemiol Prev 2013,37(1) Suppl 1:1-296. Available at: http://www.registri-tumori.it/cms/it/Rapp2012
101. Maddams J, Utley M, Møller H. Levels of acute health service use among cancer survivors in the United Kingdom. Eur J Cancer 2011;47(14):2211-20.
102. Micheli A, Mugno E, Krogh V et al. Cancer prevalence in European registry areas. Ann Oncol 2002;13(6):840-65.
103. De Angelis R, Grande E, Inghelmann R et al. Cancer prevalence estimates in Italy from 1970 to 2010. Tumori 2007;93(4):392-7.
104. AIRTUM Working Group. Italian cancer figures, Report 2010. Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients. Epidemiol Prev 2010;34(5-6) Suppl 2:1-188. Available at: http://www.registri-tumori.it/cms/?q=Rapp2010
105. Francisci S, Capocaccia R, Grande E et al. The cure of cancer: a European perspective. Eur J Cancer 2009;45(6):1067-79.
106. Dal Maso L, Guzzinati S, Buzzoni C et al; AIRTUM Working group. Long-term survival, prevalence, and cure of cancer: A population-based estimation for 818,902 Italian patients and 26 cancer types. Ann Oncol 2014;25(11):2251-60.
107. European Cancer Health Indicator Project - EUROCHIP-3. Available at: www.tumori.net/eurochip (accessed: September 2014).
108. Baili P, Hoekstra-Weebers J, Van Hoof E et al. Cancer rehabilitation indicators for Europe. Eur J Cancer 2013;49(6):1356-64.
109. PubMed. Available at: http://www.ncbi.nlm.nih.gov/pubmed/
110. Mariotto A, Warren JL, Knopf KB, Feuer EJ. The prevalence of patients with colorectal carcinoma under care in the U.S. Cancer 2003;98(6):1253-61.
111. Gatta G, Capocaccia R, Berrino F, Ruzza MR, Contiero P; EUROPREVAL Working Group. Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Ann Oncol 2004;15(7):1136-42.
112. Colonna M, Mitton N, Schott AM et al. Joint use of epidemiological and hospital medico-administrative data to estimate prevalence. Application to French data on breast cancer. Cancer Epidemiol 2012;36(2):116-21.
113. Baili P, Vicentini M, Tumino R et al; CAREMORE Group. A method for differentiating cancer prevalence according to health status, exemplified using a population-based sample of Italian colorectal cancer cases. Acta Oncol 2013;52(2):294-302.
114. Yu XQ, Clements M, O'Connell D. Projections of cancer prevalence by phase of care: a potential tool for planning future health service needs. J Cancer Surviv 2013;7(4):641-51.
115. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121(22):4439-42.
116. Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12(10):933-80.
117. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101(15):1044-8.
118. Organisation for economic co-operation and development (ed.). Cancer Care: Assuring Quality to Improve Survival. OECD Health Policy Studies. OECD Publishing 2013.
119. Elwood JM, Sutcliffe SB (eds). Cancer Control. Oxford, Oxford University Press, 2010.
120. Patto della salute 2014-2016, intesa Stato Regioni. Available at: http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=1654
121. Francisci S, Guzzinati S, Mezzetti S et al. Cost profiles of colorectal cancer patients in Italy based on individual patterns of care. BMC Cancer 2013;13:329.
122. Yabroff KR, Mariotto AB, Feuer E, Brown ML. Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ 2008;17(8):947-59.
123. Mariotto A, Yabroff KR, Feuer EJ, De Angelis R, Brown M. Projecting the number of patients with colorectal cancer by phases of care in the US: 2000-2020. Cancer Causes Control 2006;17(10):1215-26.
124. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40(8) Suppl:IV-104-17.
125. Gigli A, Warren JL, Yabroff KR et al. Initial treatment for newly diagnosed elderly colorectal cancer Pptients: patterns of care in Italy and the United States. J Natl Cancer Inst Monogr 2013;2013(46): 88-98.
126. AIRTUM Working Group. Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients. Epidemiol Prev 2010;34(5-6) Suppl 2:1-186.
127. Crocetti E, De Angelis R, Buzzoni C et al; AIRTUM Working Group. Cancer prevalence in United States, Nordic Countries, Italy, Australia, and France: an analysis of geographic variability. Br J Cancer 2013;109(1):219-28.
128. Capocaccia R, De Angelis R. Estimating the completeness of prevalence based on cancer registry data. Stat Med 1997;16(4):425-40.
129. Verdecchia A, Capocaccia R, Egidi V, Golini A. A method for the estimation of chronic disease morbidity and trends from mortality data. Stat Med 1989;8(2):201-16.
130. National Cancer Institute. Complete prevalence (comPrev) Software. Version 1.0, 2005. Available at: http://surveillance.cancer.gov/comprev/
131. Rossi S, Capocaccia R, De Angelis R, Gatta G (eds). Cancer burden in Italian regions. Tumori 2013;99(3).
132. Italian National Institute of Statistics - ISTAT. Available at: www.istat.it
133. Capocaccia R, Gavin A, Hakulinen T, Lutz JM, Sant M (eds). Survival of cancer patients in Europe, 1995-2002: the EUROCARE-4 study. Eur J Cancer 2009;45:901-1094.
134. Micheli A, Francisci S, Baili P, De Angelis R. Current cancer profiles of the Italian regions. Tumori 2007;93(4):329-407.
135. De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 1999;18(4):441-54.
136. Ventura L, Miccinesi G, Sacchettini C, De Angelis R. Estimating all cancers incidence with the MIAMOD model: a new method to include multiple tumors. Tumori 2012;98(3):296-302.
137. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer 2006;119(10):2417-22.
138. European Parliament and Council of the European communities. Decision No. 1295/99/EC of the European Parliament and of the Council of 29 April 1999 adopting a programme of community action on rare diseases within the framework for action in the field of public health (1999-2003). Official Journal of the European Communities 1999;42.
139. RARECAREnet - Information Network on Rare Cancers. Available at: www.rarecarenet.eu
140. Gatta G, van der Zwan JM, Casali PG et al; RARECARE Working Group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011;47(17):2493-511.
141. Pathological and genetic classifications of different tumours are available at: http://www.iarc.fr/en/publications/pdfs-online/pat-gen/
142. Trama A, Mallone S, Ferretti S et al. The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori 2012;98(5):550-8.
143. Mallone S, De Angelis R, van der Zwan JM et al; RARECARE Working Group. Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. Cancer Epidemiol 2013;37(6):850-6.
144. AIOM, CCM, AIRTUM Working Group. I numeri del cancro in Italia 2013. Brescia, Intermedia Editore, 2013. Available at: http://www.registri-tumori.it/cms/it/node/2888
145. Mitchell AJ, Chan M, Bhatti H et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 2011;12(2):160-74.
146. Grassi L, Riba M (eds). Clinical Psycho-Oncology: An International Perspective. Chichester, Wiley, 2012
147. Biondi M, Costantini A, Wise TN (eds). Psycho-Oncology. Arlington, American Psychiatric Publishing, 2013. (Traduzione italiana: Psiconcologia. Milano, Raffaello Cortina, 2014).
148. Grassi L, Johansen C, Annunziata MA et al; Italian Society of Psycho-Oncology Distress Thermometer Study Group. Screening for distress in cancer patients: a multicenter, nationwide study in Italy. Cancer 2013;119(9):1714-21.
149. Langeveld NE, Grootenhuis MA, Voûte PA, de Haan RJ. Posttrau-matic stress symptoms in adult survivors of childhood cancer. Pediatr Blood Cancer 2004;42(7):604-10.
150. McDonnell G, Baily C, Schuler T, Verdeli H. Anxiety among adolescent survivors of pediatric cancer: A missing link in the survivorship literature. Palliat Support Care 2014:1-5.
151. Manning JC, Hemingway P, Redsell SA. Long-term psychosocial impact reported by childhood critical illness survivors: a systematic review. Nurs Crit Care 2014;19(3):145-56.
152. Foster C, Wright D, Hill H, Hopkinson J, Roffe L. Psychosocial implications of living 5 years or more following a cancer diagnosis: a systematic review of the research evidence. Eur J Cancer Care (Engl) 2009;18(3):223-47.
153. Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M. It's not over when it's over: long-term symptoms in cancer survivors - a systematic review. Int J Psychiatry Med 2010;40(2):163-81.
154. Valdivieso M, Kujawa AM, Jones T, Baker LH. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci 2012;9(2):163-73.
155. th employment, social policy, health and consumer affairs Council meeting. Luxembourg, 10 June 2008. Available at: www.eu2008.si/en/News_and_Documents/Council_Conclusions/June/0609_EPSCO-cancer.pdf
156. Grassi L, Watson M; IPOS Federation of Psycho-Oncology Societies' co-authors. Psychosocial care in cancer: an overview of psychosocial programmes and national cancer plans of countries within the International Federation of Psycho-Oncology Societies. Psychooncology 2012;21(10):1027-33.
157. Bultz BD, Cummings GG, Grassi L, Travado L, Hoekstra-Weebers J, Watson M. 2013 President's Plenary International Psycho-oncology Society: embracing the IPOS standards as a means of enhancing comprehensive cancer care. Psychooncology 2014;23(9):1073-8.
158. Grassi L, Costantini A. Il distress emozionale in oncologia come sesto parametro vitale. In: Osservatorio sulla condizione assistenziale dei malati oncologici. 4° Rapporto sulla condizione assistenziale dei malati oncologici. Roma 2012, pp. 247-51.
159. Costantini A, Lucchini D, Geraci D. Censimento dell'assistenza psi-cooncologica in Italia: quali servizi e quali professionisti. In: Osservatorio sulla condizione assistenziale dei malati oncologici. 5° Rapporto sulla condizione assistenziale dei malati oncologici; Roma 2013, pp. 111-5.
160. Grassi L, Costantini A, Lucchini D, Busco S. Il contraddittorio bilancio della Psiconcologia in Italia: cresce la domanda di assistenza psicologica ai malati oncologici e si riducono i servizi per contenere le spese. In: Osservatorio sulla condizione assistenziale dei malati oncologici. 6° Rapporto sulla condizione assistenziale dei malati oncologici. Roma 2014, pp. 85-9.
161. Società Italiana di Psicooncologia (SIPO). Standard, opzioni e raccomandazioni per una buona pratica psiconcologica. Roma, CIC Edi-zioni Internazionali, 2011.
162. Associazione Italiana di Oncologia Medica (AIOM). Linee guida. As-sistenza psico-sociale dei malati oncologici. AIOM, 2013. Available at: http://www.aiom.it/C_Common/Download.asp?file=/$Site$/Attivita_Scientifica/Linee_Guida/2013/Psicosociale_v7_18.9.13.pdf
163. Ministro della Salute, Direzione Generale Programmazione Sanita-ria. Definizione degli standard qualitativi, strutturali, tecnologici e quantitativi relativi all'assistenza ospedaliera. 5 Agosto 2014. Available at: http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=1694
164. De Lorenzo F. Cancer Survivorship: Europe: Inequalities and Actions. Cancer 2013;119 Suppl 11:2089-90.
165. De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15(1):23-34.
166. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14(12):1165-74.
167. Osservatorio sulla condizione assistenziale dei malati oncologici. 4° Rapporto sulla condizione assistenziale dei malati oncologici. VII Giornata nazionale del malato oncologico. Roma, 15-20 maggio 2012. FAVO 2012. Available at: http://favo.it/quarto-rapporto.html
168. Janssen-Heijnen ML, Gondos A, Bray F et al. Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. J Clin Oncol 2010;28(15):2520-8.
169. Baade PD, Youlden DR, Chambers SK. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust 2011;194(2):73-7.
170. Dal Maso L, Guzzinati S, Buzzoni C et al. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818,902 Italian patients and 26 cancer types. Ann Oncol 2014; 25(11):2251-60.
171. Yabroff KR, Francisci S, Mariotto A, Mezzetti M, Gigli A, Lipscomb J. Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities. J Natl Cancer Inst Monogr 2013;2013(46):1-6.
172. Casali PG; European Society for Medical Oncology (ESMO) Switzerland. Risks of the new EU Data Protection Regulation: an ESMO position paper endorsed by the European oncology community. Ann Oncol 2014;25(8):1458-61.
173. Cancer Control Joint Action (CanCon). 08 - Survivorship and rehabilitation. 2014. Available at: http://www.cancercontrol.eu/how-wework/survivorship-and-rehabilitation